WuXi AppTec

WuXi AppTec

Global contract research, development, manufacturing organization

Business Development Manager / Senior Manager - TIDES in Europe

Full-TimeDeadline 9/14/27
No salary listed
Junior
Master's, PhD
Germany
Hybrid

Applicants must have the legal right to work in Germany. Travel of 35% is required.

About the job

Requirements
  • An advanced degree in chemistry or a related science field is required.
  • At least 1 year of relevant experience working in new drug development or the contract research or contract manufacturing organization industry is required.
  • Experience with oligonucleotides and peptides is strongly preferred.
  • A proven track record of meeting or exceeding sales growth objectives and/or simultaneously managing several projects and timelines is required.
  • Experience with customer relationship management software is preferred.
  • The ability to use computer equipment and software, including Microsoft Word, Excel, Outlook, PowerPoint, and customer relationship management software, is required.
  • The ability to perform within a professional environment and use judgment according to the complexity of the situation is required.
  • The candidate must be self-motivated, flexible, organized, and detail-oriented, with verbal, written, and presentation communication skills.
  • The candidate must have the legal right to work in Germany at the time of application.
  • The candidate must be able to travel 35%.
Responsibilities
  • Prospect for oligonucleotide and peptide new drug development companies that would benefit from WuXi TIDES Discovery Services.
  • Uncover and cultivate business relationships and revenue-generating opportunities with prospective and existing oligonucleotide and peptide clients.
  • Develop, grow, and maintain key Discovery oligonucleotide and peptide accounts in WuXi Chemistry.
  • Achieve purchase-order targets for key accounts and new accounts.
  • Attend conferences and meetings to present WuXi TIDES Discovery services to prospective and existing clients through email, phone, and web-conferencing systems.
  • Act upon, refer, and follow up on leads from sales and marketing campaigns.
  • Qualify leads and work with necessary team members to complete requests for quotation and requests for proposal.
  • Work closely with WuXi business units, project management teams, and marketing to coordinate efforts and maintain communication.
  • Increase awareness of STA/TIDES marketing initiatives, including scheduling meetings for trade shows and driving registrations for webinars and seminars.
  • Stay abreast of industry trends, funding, regulatory influences, mergers and acquisitions, product and technology in-licensing and out-licensing, government and private grants and contacts, new drug development and approvals, patent grants and notifications, and market growth of small-, medium-, and large-cap companies.
  • Develop a social network of industry-related contacts through LinkedIn and other social networking platforms.
  • Develop quarterly business-development plans and benchmark performance for continued success.
  • Propose ideas and strategies to increase performance and achieve personal and team goals.
  • Document client information in the customer relationship management system, including contacts, pre-screened and qualified leads, and new account information.
Desired Qualifications
  • A Ph.D. is preferred.
  • Experience with oligonucleotides and peptides is strongly preferred.
  • Experience with customer relationship management software, such as Salesforce, is preferred.

About the company

What WuXi AppTec does: It provides a global, integrated open-access platform for contract research, development, and manufacturing services (CRDMO) to the pharmaceutical, biotechnology, and medical device industries. How its products work: Clients access a broad portfolio of capabilities—laboratory testing, process development, and manufacturing—across the full product lifecycle, from discovery and preclinical work to clinical and commercial production, often supported by strategic acquisitions to extend reach. How it differs from competitors: It combines extensive geographic reach with a wide, end-to-end service portfolio in one platform, rather than focusing on a narrow stage or region. What its goal is: To help innovators bring new medicines and healthcare products to market faster and with high quality.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Huangpu, China

Founded

2000

Get referred to WuXi AppTec

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • WuXi AppTec raised 2026 revenue guidance to RMB 58.5-60.5 billion on August 3, 2026.
  • H1 2026 revenue rose 38.9%, and backlog reached RMB 66.43 billion.
  • Delaware starts Q4 2026 and Singapore starts 2027, expanding non-China manufacturing capacity.

What critics are saying

  • On June 8, 2026, DoD added WuXi AppTec to the 1260H Chinese military list.
  • Customers terminated, paused, and redirected programs within weeks after the June 2026 designation.
  • If BIOSECURE targets WuXi in December 2026, U.S. business continuity faces existential damage.

What makes WuXi AppTec unique

  • WuXi AppTec’s integrated CRDMO spans discovery, development, and manufacturing across 30-plus countries.
  • Its 2026 capacity buildout covers Delaware, Singapore, Taixing, and Switzerland simultaneously.
  • DMPK compound management serves thousands of clients with one-million-plus compound storage and traceability.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 0%
PR Newswire
Aug 3rd, 2026
WuXi AppTec H1 revenue surges 39% to $4B, raises 2026 guidance amid US defence list inclusion

WuXi AppTec reported strong first-half 2026 results and raised its full-year guidance. The Chinese pharmaceutical contract research, development, and manufacturing organisation posted H1 revenue of RMB 28.90 billion, up 38.9% year-on-year, with continuing operations revenue rising 48.0%. Adjusted non-IFRS net profit increased 83.2% to RMB 11.57 billion, whilst the gross profit margin expanded 9.4 percentage points to 53.9%. The company's backlog for continuing operations grew 25.2% to RMB 66.43 billion as of 30 June 2026. WuXi AppTec raised its 2026 total revenue target to RMB 58.5–60.5 billion, up from RMB 51.3–53.0 billion previously. The firm also increased its capital expenditure guidance to RMB 7.5–8.5 billion to support accelerated global capacity expansion. The company addressed its inclusion on the US Department of Defence's 1260H list, calling it erroneous and confirming legal action to protect stakeholder interests.

Associated Press
Jul 7th, 2026
WuXi AppTec launches automated compound management system with fourfold storage density and full traceability

WuXi AppTec DMPK has launched an automated compound management platform serving thousands of pharmaceutical and biotechnology companies worldwide, with storage capacity exceeding one million compounds. The system provides full lifecycle management through digital operations, featuring automated robotic retrieval, real-time weighing data integration with high-precision balances, and automated preparation via Hamilton systems. The platform addresses three major challenges in drug metabolism and pharmacokinetics research: diverse container types, large compound libraries, and strict storage requirements. Key capabilities include real-time logistics tracking, image recognition-based automated picking, and high-density mobile storage delivering approximately fourfold capacity versus fixed-cabinet layouts. The system maintains tamper-proof audit logs and role-based access control whilst integrating with the Mosaic Compound Management System. WuXi AppTec DMPK offers flexible managed services covering sample receipt, secure storage, distribution, and disposal, aiming to reduce operational costs and accelerate research timelines.

Associated Press
Jun 11th, 2026
WuXi AppTec expands peptide and oligonucleotide capacity, eyes 40% revenue growth in 2026

WuXi AppTec is expanding its global manufacturing capabilities for emerging drug modalities including peptides, oligonucleotides and targeted protein degraders, according to Pharma Manufacturing. The company's WuXi TIDES platform, focused on oligonucleotides and peptides, is projected to achieve approximately 40% year-on-year revenue growth in 2026. The company's solid-phase peptide synthesis reactor volume exceeded 100,000 litres at end-2025 and is expected to reach 130,000 litres by end-2026. New production facilities are under construction in Taixing, China, scheduled for 2027 operation, and Singapore, planned for 2028. WuXi AppTec is investing in process technologies combining solid-phase and liquid-phase synthesis to improve scalability for complex molecules. The company is also developing integrated approaches for antibody-drug conjugates and targeted protein degraders, incorporating earlier-stage chemistry and biology integration.

Yahoo Finance
Jun 9th, 2026
WuXi AppTec added to Pentagon's Chinese military list, vows to challenge 'erroneous designation

WuXi AppTec has been added to the Pentagon's list of "Chinese military companies", escalating tensions between the pharmaceutical manufacturer and the US. The Department of Defence updated its Section 1260H list on 8 June, adding WuXi alongside other Chinese firms including BYD and Comac. The DoD claims WuXi has links to China's State Administration for Science, Technology and Industry for National Defence and the People's Liberation Army. WuXi strongly denied the designation, calling it "clearly a mistake" and stating it is not owned, controlled or affiliated with any Chinese military or government entity. The contract research and manufacturing organisation, which operates in over 30 countries, reported revenues of $1.83 billion in Q1 2026, up 39.4% year-over-year. WuXi was previously removed from the BIOSECURE Act in October 2025.

Associated Press
Jun 5th, 2026
WuXi AppTec boosts capex 17% to $77M-$89M for global manufacturing expansion

WuXi AppTec is accelerating global manufacturing expansion across the United States, Europe and Asia, increasing capital expenditures by at least 17% this year to between RMB 6.5 billion and RMB 7.5 billion. The pharmaceutical contract research, development and manufacturing organisation is responding to growing customer demand, particularly for peptides and oligonucleotides. The company's new Middletown, Delaware facility will begin oral solid dosage manufacturing in Q4 2026, becoming its largest US site at 1.74 million square feet. In Europe, WuXi is expanding its Couvert, Switzerland site, whilst a Singapore facility is expected to begin Phase I operations in 2027. WuXi AppTec's small molecule pipeline reached 3,550 molecules by end-March 2026. Its TIDES business is projected to grow approximately 40% year-over-year.